AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35310783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prediction model for cancer-specific survival (CSS)
Number of subjects: 33509
Study 35247102 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing ARB/CCB combination tablets (Group C)
Number of subjects: 106
Study 35247102 — intervention group
Group type: COMPARATOR
Intervention: Withholding ARB/CCB combination tablets (Group W)
Number of subjects: 106
Study 33502511 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day point prevalence smoking abstinence
Number of subjects: 1751
Study 33502511 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day abstinence from smoking and nicotine
Number of subjects: 1751
Study 33502511 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month prolonged abstinence
Number of subjects: 1751
Study 34558061 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational program based on the rational emotional behavioral approach
Number of subjects: 0
Study 34915452 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive lower limb training (E1, E2, E3)
Number of subjects: 30
Study 34847709 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN)
Number of subjects: 27
Study 34847709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 27
Study 34847709 — intervention group
Group type: EXPERIMENTAL
Intervention: Any medication (ISMN or cilostazol)
Number of subjects: 27
Study 34847709 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 27
Study 32590960 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and MRI analysis
Number of subjects: 29
Study 32590960 — intervention group
Group type: EXPERIMENTAL
Intervention: CT analysis
Number of subjects: 29
Study 32590960 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and CT analysis
Number of subjects: 29
Study 32590960 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis
Number of subjects: 29
Study 35338177 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 50 mg daily for 14 days
Number of subjects: 32
Study 35338177 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 200 mg daily for 14 days
Number of subjects: 32
Study 35338177 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 500 mg daily for 14 days under fed conditions
Number of subjects: 32
Study 35338177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 35338177 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian (all doses)
Number of subjects: 32
Study 34339232 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous semaglutide
Number of subjects: 0
Study 34339232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of 11 km·h‐1
Number of subjects: 18
Study 32723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of 12 km·h‐1
Number of subjects: 18
Study 32723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of 13 km·h‐1
Number of subjects: 18
Study 32723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of 14 km·h‐1
Number of subjects: 18
Study 32723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of speed on all absolute values except push-off force
Number of subjects: 18
Study 32723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetry in variables
Number of subjects: 18
Study 32723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased gait speed
Number of subjects: 18
Study 34551146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic narrow-diameter implants (Neoporos surface, NS)
Number of subjects: 16
Study 34551146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic narrow-diameter implants (Acqua surface, AS)
Number of subjects: 16
Study 34551146 — intervention group
Group type: COMPARATOR
Intervention: Control group (NS)
Number of subjects: 16
Study 33585276 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva
Number of subjects: 25101
Study 33585276 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival plaque
Number of subjects: 25101
Study 33585276 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐Based Cohort Study
Number of subjects: 25101
Study 33585276 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth and Three‐Generation Cohort Study
Number of subjects: 25101
Study 33585276 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence network analysis
Number of subjects: 25101
Study 33593462 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic ice cream supplementation for 30 days containing 2·1 × 10^8 CFU/g for Lactobacillus acidophilus LA‐5, 2·7 × 10^9 CFU/g for Bifidobacterium animalis BB‐12, and 2·3 g of inulin in 60 g of ice cream.
Number of subjects: 65
Study 33593462 — intervention group
Group type: COMPARATOR
Intervention: Placebo ice cream.
Number of subjects: 65
Study 33593462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (synbiotic and placebo).
Number of subjects: 65
Study 33593462 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic ice cream supplementation.
Number of subjects: 65
Study 35182217 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue Laser Imaging (BLI)
Number of subjects: 164
Study 35182217 — intervention group
Group type: COMPARATOR
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 164
Study 33939625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweets indicating capability factors (P<.001)
Number of subjects: 5000
Study 33939625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweets indicating motivation factors (P<.001)
Number of subjects: 5000
Study 33939625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweets indicating opportunity factors (P=.03)
Number of subjects: 5000
Study 33939625 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall behavioral intentions from tweets
Number of subjects: 5000
Study 33384892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient-boosting decision tree model using preoperative biometry and patient sex as predictors
Number of subjects: 847
Study 33384892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient-boosting decision tree model excluding keratometry
Number of subjects: 847
Study 33384892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient-boosting decision tree model using IOL power as an additional predictor
Number of subjects: 847
Study 33384892 — intervention group
Group type: COMPARATOR
Intervention: Five existing methods (control)
Number of subjects: 847
Study 32905628 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 859
Study 32905628 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 859
Study 32905628 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum glucose levels
Number of subjects: 859
Study 32349543 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability training (24 sessions)
Number of subjects: 44
Study 34789539 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Number of subjects: 0
Study 34789539 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic treatment
Number of subjects: 0
Study 32735711 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐mm 6‐0, 5‐0, and 4‐0 nylon monofilaments
Number of subjects: 22
Study 35246227 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg administered enterally every 8 hours
Number of subjects: 0
Study 35246227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35712945 — intervention group
Group type: EXPERIMENTAL
Intervention: Wei's triple nine needling combined with esculin and digitalis glycosides eye drops
Number of subjects: 46
Study 35712945 — intervention group
Group type: COMPARATOR
Intervention: Esculin and digitalis glycosides eye drops alone
Number of subjects: 46
Study 33602209 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie‐Duo
Number of subjects: 162
Study 33602209 — intervention group
Group type: COMPARATOR
Intervention: ART
Number of subjects: 162
Study 33140104 — intervention group
Group type: EXPERIMENTAL
Intervention: Jeopardy-style educational game show-based intervention
Number of subjects: 38
Study 33140104 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic-based curriculum
Number of subjects: 38
Study 35020871 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine (0.5 mg/kg) infusions
Number of subjects: 186
Study 35020871 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 186
Study 34518580 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary sinus saline irrigation after surgery
Number of subjects: 40
Study 34518580 — intervention group
Group type: COMPARATOR
Intervention: Caldwell-Luc procedure
Number of subjects: 40
Study 33065070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 30
Study 33065070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 30
Study 32514736 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world evidence (RWE)
Number of subjects: 0
Study 32514736 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing healthcare and patient-generated data
Number of subjects: 0
Study 32514736 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring patient safety in randomized trials
Number of subjects: 0
Study 32514736 — intervention group
Group type: EXPERIMENTAL
Intervention: Study design and methodological options specific to PCTs
Number of subjects: 0
Study 32514736 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practices to ensure data quality in PCTs
Number of subjects: 0
Study 34342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management (uterine evacuation followed by methotrexate if needed)
Number of subjects: 255
Study 34342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management (empirical methotrexate using a 2-dose protocol)
Number of subjects: 255
Study 34342619 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 255
Study 32229417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary education
Number of subjects: 9255
Study 32229417 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary education
Number of subjects: 9255
Study 36112726 — intervention group
Group type: EXPERIMENTAL
Intervention: Year 4 trainees
Number of subjects: 100
Study 36112726 — intervention group
Group type: COMPARATOR
Intervention: Year 3 trainees
Number of subjects: 100
Study 36112726 — intervention group
Group type: COMPARATOR
Intervention: Year 2 trainees
Number of subjects: 100
Study 35297138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional PPD with low dose isotretinoin for a 3-month course
Number of subjects: 0
Study 35297138 — intervention group
Group type: COMPARATOR
Intervention: Intralesional PPD monotherapy at 2-week intervals for up to six sessions
Number of subjects: 0
Study 34768411 — intervention group
Group type: EXPERIMENTAL
Intervention: HILT (7 W, 149.9 J/cm2, 1064 nm, 4496 J, 12 min)
Number of subjects: 60
Study 34768411 — intervention group
Group type: COMPARATOR
Intervention: Sham HILT therapy (placebo)
Number of subjects: 60
Study 33896825 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum plus etoposide chemotherapy (CT)
Number of subjects: 911
Study 32064794 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg QD from days 1 to 14 of a 21-day cycle)
Number of subjects: 437
Study 32064794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 35273066 — intervention group
Group type: EXPERIMENTAL
Intervention: Management guided by both ICP and PbtO2 monitoring
Number of subjects: 1094
Study 35273066 — intervention group
Group type: COMPARATOR
Intervention: Management guided by ICP alone
Number of subjects: 1094
Study 33618193 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated exposure therapy
Number of subjects: 110
Study 33618193 — intervention group
Group type: COMPARATOR
Intervention: Integrated coping skills therapy
Number of subjects: 110
Study 32756078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sancai powder (SC) combined with western medicine
Number of subjects: 60
Study 32756078 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine
Number of subjects: 60
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: New insights into prostate cancer biology and treatment
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs and drug targets in prostate cancer
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Advances in prostate cancer genomics
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lessons from the multi‐arm, multistage randomized phase 3 STAMPEDE trial
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Advances in immunotherapy for prostate cancer
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors contributing to prostate cancer racial disparities
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment‐associated small‐cell/neuroendocrine prostate cancer (t‐SCNC)
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence and machine learning in cancer research and development
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Population science research on prostate cancer
Number of subjects: 0
Study 33085787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer research in the Department of Veterans Affairs
Number of subjects: 0
Study 32493240 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside (IIM-Diafer®)
Number of subjects: 190
Study 32493240 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS-Venofer®)
Number of subjects: 190
Study 86062952 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mug of HBsAg intradermally on days 0, 30, and 180
Number of subjects: 50
Study 86062952 — intervention group
Group type: COMPARATOR
Intervention: 20 mug of HBsAg intramuscularly on days 0, 30, and 180
Number of subjects: 50
Study 36066864 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital narrative-based bibliotherapy (reading one suicide narrative per day for 14 days)
Number of subjects: 528
Study 36066864 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 528
Study 33436401 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone for 12 months
Number of subjects: 438
Study 33436401 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine for 3 months followed by metformin for 9 months
Number of subjects: 438
Study 36111381 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of DIM (administered as 300 mg of DIM‐BR®) for 30 days
Number of subjects: 60
Study 36111381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35976136 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 385
Study 35976136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 33765679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exercise training at 4-7 days/week
Number of subjects: 43
Study 33765679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 43
Study 34211323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant knee extensors (KE) fatigue intervention (2×100s MVC)
Number of subjects: 12
Study 34211323 — intervention group
Group type: COMPARATOR
Intervention: Control (equivalent rest)
Number of subjects: 12
Study 33296385 — intervention group
Group type: EXPERIMENTAL
Intervention: Some support
Number of subjects: 1066
Study 33296385 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-oriented goals
Number of subjects: 1066
Study 33296385 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance-oriented goals
Number of subjects: 1066
Study 33296385 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 1066
Study 33296385 — intervention group
Group type: COMPARATOR
Intervention: Extended support
Number of subjects: 1066
Study 35235082 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDT plus HIIT
Number of subjects: 16
Study 35235082 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus HIIT
Number of subjects: 16
Study 34404606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 178
Study 34404606 — intervention group
Group type: COMPARATOR
Intervention: Health Education and Wellness training (HEW)
Number of subjects: 178
Study 32614699 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg/day for 8 weeks)
Number of subjects: 34
Study 32614699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32614699 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 34
Study 32614699 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide and Placebo
Number of subjects: 34
Study 35894434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 104
Study 35894434 — intervention group
Group type: COMPARATOR
Intervention: No PFMT (Control)
Number of subjects: 104
Study 34750366 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfectant spray
Number of subjects: 72
Study 34750366 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfectant wipe
Number of subjects: 72
Study 34750366 — intervention group
Group type: COMPARATOR
Intervention: Control (not cleaned)
Number of subjects: 72
Study 34648751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple shields for persistent nipple pain
Number of subjects: 25
Study 34543939 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence training (twice a week for one month, then once a week for 11 months)
Number of subjects: 103
Study 34543939 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily briefings without emotional intelligence training)
Number of subjects: 103
Study 34543939 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence training
Number of subjects: 103
Study 32065620 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg/kg/day, 48 hours intravenous infusion)
Number of subjects: 58
Study 32065620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32065620 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 58
Study 36343592 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg single oral dose)
Number of subjects: 21832
Study 36343592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 21832
Study 33530942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose TXA
Number of subjects: 30
Study 33530942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TXA
Number of subjects: 30
Study 33530942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32902312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (N) alone or combined with ipilimumab (I) as neoadjuvant therapy after 6 months of adjuvant therapy
Number of subjects: 276
Study 32902312 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy as first-line treatment
Number of subjects: 276
Study 32902312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (N) alone or combined with ipilimumab (I)
Number of subjects: 276
Study 32902312 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 276
Study 35973802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab induction therapy
Number of subjects: 189
Study 35973802 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/azathioprine
Number of subjects: 189
Study 33533690 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis positive contacts (N = 82)
Number of subjects: 891
Study 33533690 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia trachomatis negative contacts
Number of subjects: 891
Study 33533690 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis positive contacts
Number of subjects: 891
Study 34753815 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-volume nebulizer (SVN)
Number of subjects: 9
Study 34753815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating mesh nebulizer (VMN)
Number of subjects: 9
Study 34753815 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask with exhalation filter (SVN)
Number of subjects: 9
Study 34753815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece with exhalation filter (VMN)
Number of subjects: 9
Study 34753815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhalo scavenger over the mask (SVN)
Number of subjects: 9
Study 34753815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapotherm scavenger and filter face mask
Number of subjects: 9
Study 34753815 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece
Number of subjects: 9
Study 34753815 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 9
Study 33269509 — intervention group
Group type: EXPERIMENTAL
Intervention: DFF-based glucose fluctuation metric
Number of subjects: 137
Study 33872452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest score for HIT diagnosis
Number of subjects: 2280
Study 32312242 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedication review using tele-expertise
Number of subjects: 364
Study 32312242 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 364
Study 35022178 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy, delivered by specialised exercise and physical therapists, a multimodal and tailored treatment based on the biopsychosocial model.
Number of subjects: 20
Study 35022178 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy, delivered by specialised exercise and physical therapists.
Number of subjects: 20
Study 34682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 100
Study 34682735 — intervention group
Group type: COMPARATOR
Intervention: Biscuits
Number of subjects: 100